Loading Events

« All Events

Cardiovascular and Renal Drugs Advisory Committee

July 15

The committee will discuss new drug application (NDA) 213805, for the hypoxia inducible factor prolyl hydroxylase inhibitor, roxadustat tablets, submitted by FibroGen, Inc., for the treatment of anemia due to chronic kidney disease in adult patients not on dialysis and on dialysis.


July 15
Event Category: